Edwyn
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | $213 | $196 | $188 | $172 | $317 |
| Gross Profit | $151 | $135 | $154 | $140 | $231 |
| Operating Income | $37 | $22 | $33 | $3 | $81 |
| Net Income | $32 | $14 | $12 | -$9 | $36 |
Over the five-year period, Eagle Pharmaceuticals’ income statement data shows a mixed performance with notable volatility. Between 2018 and 2021, revenue and profitability metrics trended downward. Revenue declined from US$213.3 million in 2018 to US$171.5 million in 2021, while gross profit decreased from US$151.4 million to US$140.0 million over the same period. Operating income experienced a steep drop—from US$36.6 million in 2018 to a low of US$2.8 million in 2021—and net income fell significantly from US$31.9 million in 2018 to a loss of US$8.6 million in 2021. The swings between 2020 and 2021 are particularly significant, with net income turning negative and operating income plunging by over 90% from 2020 to 2021. These sharp declines may reflect operational challenges or heightened cost pressures within a competitive specialty pharmaceutical market, although the data does not specify the exact drivers. In contrast, 2022 marked a dramatic turnaround. Revenue surged to US$316.6 million—an increase of approximately 84% from 2021—while gross profit climbed by a similar margin to US$231.2 million, indicating strong recovery in core business operations. Operating income rebounded to US$81.0 million, and net income improved to US$35.6 million, signaling a significant overhaul in operational efficiency and profitability. Although the mid-period volatility raises concerns about consistency, the robust recovery in 2022 suggests that the company may have implemented corrective measures or capitalized on favorable market conditions. Overall, while the recent recovery is encouraging, sustained financial health will depend on maintaining growth momentum and managing operational risks in a challenging industry landscape.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.